Smart Digital Group Limited (SDM)

ASLAN Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Revenue	21.52	9.7	1.83
Revenue Growth (YoY)	121.80%	428.96%	-
Cost of Revenue	18.53	6.49	1.39
Gross Profit	2.99	3.21	0.45
Selling, General & Admin	0.92	0.93	0.28
Operating Expenses	0.92	0.93	0.28
Operating Income	2.07	2.29	0.17
Interest Expense	-0.02	-0.02	-0
Interest & Investment Income	0	0	0
Currency Exchange Gain (Loss)	-0	-	-
Other Non Operating Income (Expenses)	-0	-0	-
Pretax Income	2.05	2.26	0.16
Income Tax Expense	0.35	0.27	0.03
Net Income	1.7	1.99	0.13
Net Income to Common	1.7	1.99	0.13
Net Income Growth	-14.88%	1404.86%	-
Shares Outstanding (Basic)	25	25	25
Shares Outstanding (Diluted)	25	25	25
EPS (Basic)	0.07	0.08	0.01
EPS (Diluted)	0.07	0.08	0.01
EPS Growth	-14.88%	1404.91%	-
Free Cash Flow	-0.7	-0.22	0.03
Free Cash Flow Per Share	-0.03	-0.01	0.00
Gross Margin	13.89%	33.10%	24.33%
Operating Margin	9.63%	23.56%	9.16%
Profit Margin	7.88%	20.54%	7.22%
Free Cash Flow Margin	-3.25%	-2.25%	1.43%
EBITDA	2.08	2.29	0.17
EBITDA Margin	9.69%	23.65%	9.22%
D&A For EBITDA	0.01	0.01	0
EBIT	2.07	2.29	0.17
EBIT Margin	9.63%	23.56%	9.16%
Effective Tax Rate	17.28%	12.00%	19.62%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q